LUPIN LATEST NEWS UPDATE

Lupin has signed a license and supply agreement with China's Sino Universal Pharmaceuticals for the commercialization of its Tiotropium dry powder inhaler (DPI) in the Chinese market. This partnership, announced on June 16, 2025, aims to expand Lupin's presence in China and enhance patient access to high-quality respiratory disease treatments, with Lupin responsible for manufacturing the product and Sino Universal for regulatory approvals and sales. In terms of regulatory approvals and product launches, Lupin recently received tentative approval from the US FDA for its Oxcarbazepine extended-release (ER) tablets, intended for the US market and to be manufactured at Lupin's Nagpur facility. This follows earlier US FDA approval for Raltegravir Tablets USP, 600 mg, for which Lupin has exclusive first-to-file status and 180-day generic exclusivity. In May 2025, Lupin also launched Tolvaptan Tablets in the US, used to slow kidney function decline, holding exclusive first-to-file status for this product. Lupin also announced a strategic partnership with SteinCares in May 2025 for the licensing and supply of Lupin's biosimilar Ranibizumab across Latin American markets (excluding Mexico and Argentina). This collaboration leverages SteinCares' distribution network and Lupin's manufacturing capabilities to enhance the availability of innovative healthcare solutions in the region. From a financial perspective, Lupin reported a strong Q1 FY25 with a significant year-on-year increase in profit after tax (PAT) and operating profit. North America and India formulation sales showed healthy growth, contributing significantly to Lupin's overall sales mix. The company's R&D investment for the quarter was INR 3,500 Mn (6.3% of sales), reflecting its commitment to innovation.